Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
A new study on the BC experience with biosimilars found that "Well-supported switching to biosimilars, in the form of solid education efforts about biosimilar equivalence, leads to successful clinical outcomes and, importantly, patient acceptance of these agents."
Generics Bulletin report on Quebec becoming the fourth province in Canada to announce a biosimilar switching policy.
Quebec has become the fourth province in Canada to announce its intention to implement a biosimilar switching policy. Quebec expects to generate annual savings of $100M and plans to reinvest the savings in the healthcare system and improve access to new therapies. Available in French only.
CTV News coverage of the Quebec Government’s plans to implement a biosimilar switching policy, which is expected to save the province more than $100 million annually.
Report from the American Journal of Managed Care on the addition of Humira adalimumab to Alberta’s biosimilar switching policy. About 3,300 patients will switch to adalimumab biosimilars over the next year.
Report from the Generics Bulletin on Alberta becoming the third province in Canada to apply its biosimilar switch policy to Humira adalimumab, the #2 top-selling biologic drug in Canada.